Covid and commercial research decline

Inevitably, the rapid spread of an emergent and potentially lethal virus around the world has led to huge disruption of normal life. With talk of a new-normal in the wake of the COVID-19 pandemic, we do not yet have any way ...

COVID-19: A wake-up call to rebalance the drug supply chain?

Over 80% of chemicals used to make pharmaceuticals sold in Europe originate from China or India, according to the European Fine Chemicals Group. When COVID-19 emerged in Wuhan and spread across the globe, experts worried ...

One drug, many diseases

It seems too good to be true: a single drug that could treat humanity's worst afflictions, including atherosclerosis, cancer, Alzheimer's, Parkinson's and arthritis. All of these diseases have one thing in common—they involve ...

Harvesters of light

They fan out into lily-pad-shaped disks, branch haphazardly like the antlers of deer, and hold fast to the sea floor in squat little spheres. Corals come in many shapes and sizes—and this diversity in form is driven by ...

Drug companies warm up to continuous manufacturing

For decades, most industries, from petrochemicals to paper, have embraced continuous manufacturing processes. In contrast, the ultraconservative pharmaceutical industry has remained committed to batch operations. But recently, ...

A banner year for pharma

As 2018 draws to a close, the pharmaceutical industry is celebrating a prosperous year of new investments and therapeutic breakthroughs. These successes were driven by cutting-edge science and progress in finally translating ...

Generic drug manufacturers see new opportunities ahead

Declining prices and a saturated market could spell doom-and-gloom for the generic pharmaceutical industry, but some in the business are turning lemons into lemonade, seeing opportunities instead. According to an article ...

Pace of new drug approvals rise—and so do their price tags

Last year, more new drugs reached the market than in any year since 1996. But many have six-figure price tags for a year's worth of treatment and deliver only incremental health benefits. What does this mean for patients ...

page 20 from 22